Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Cash from Investing Activities (2018 - 2025)

Viemed Healthcare (VMD) has disclosed Cash from Investing Activities for 6 consecutive years, with -$7.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 17.24% year-over-year to -$7.6 million, compared with a TTM value of -$50.2 million through Dec 2025, down 63.41%, and an annual FY2025 reading of -$50.2 million, down 63.41% over the prior year.
  • Cash from Investing Activities was -$7.6 million for Q4 2025 at Viemed Healthcare, up from -$32.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$1.7 million in Q1 2021 and bottomed at -$32.3 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$8.8 million, with a median of -$7.0 million recorded in 2022.
  • Peak annual rise in Cash from Investing Activities hit 84.53% in 2025, while the deepest fall reached 549.97% in 2025.
  • Year by year, Cash from Investing Activities stood at -$6.6 million in 2021, then dropped by 12.42% to -$7.4 million in 2022, then decreased by 1.56% to -$7.5 million in 2023, then dropped by 22.75% to -$9.2 million in 2024, then grew by 17.24% to -$7.6 million in 2025.
  • Business Quant data shows Cash from Investing Activities for VMD at -$7.6 million in Q4 2025, -$32.3 million in Q3 2025, and -$1.7 million in Q2 2025.